For this cosmeceutical application, the companies utilized their proprietary transdermal delivery platform (TPM) to directly deliver AOD-9604 through the skin
Pregnant or breastfeeding women are typically advised against use due to insufficient research
The treatment group demonstrated measurable improvements in skin density, thickness, laxity, and fine lines compared to vehicle control
SDP has received research funding from AstraZeneca, Boehringer Ingelheim, Novartis Pharmaceuticals Co., and Merck Sharpe & Dohme, and is a consultant for or has received honoraria from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, GlaxoSmithKline, Janssen Pharmaceuticals, Laboratoires Servier, Merck Sharp & Dohme, Novartis Pharmaceuticals Co., Novo Nordisk, Sanofi, and Takeda